Brief: Vicore Pharma: Drug Candidate VP01 Demonstrates Potential
22/06/2020 07:13
June 22 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* DRUG CANDIDATE VP01 DEMONSTRATES POTENTIAL FOR SIGNIFICANT
BENEFIT IN SEVERE PULMONARY HYPERTENSION
* VP01 SIGNIFICANTLY REDUCED SMALL VESSEL VASCULOPATHY THAT
CAUSED
RIGHT VENTRICLE REMODELING AND IMPROVED HEART FUNCTION
Source text for Eikon: ID:nWkr6g1XGd
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2